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Summary and Implications  
 A major hurdle to swine influenza vaccination of 
young piglets is maternal antibody interference. This 
interference is transient as it disappears when pigs reach 
about 3 months of age.  We vaccinated piglets without 
and with interfering maternal antibody using a 
recombinant vector vaccine. In the absence of interfering 
maternal antibody, the vaccine was effective in inducing a 
strong immune response and greatly reduced the amount 
of virus. However, this same recombinant vaccine was not 
effective when interfering maternal antibodies were 
present.  We are currently trying a higher dose of vaccine 
and different genes from SIV in hopes we can overcome 
this maternal antibody. Preliminary data from these new 
studies are promising.  
 
Introduction 
 Swine influenza virus (SIV) causes serious disease in 
the swine industry due to clinical disease, delayed time to 
market, and zoonotic potential. A major hurdle for SIV 
vaccination in young piglets is maternally derived 
antibodies. This passive immunity is beneficial for 
protecting newborn piglets from clinical disease but 
detrimental to the induction of active immunity. Because 
antibodies to SIV in colostrum can cause current vaccines 
to fail, delayed vaccination following antibody decay is 
routinely practiced. This causes a period of time in which 
piglets are susceptible to influenza due to declining 
maternal immunity and prior to vaccine induced 
immunity. The use of recombinant vectors which mimic 
natural infection by producing high levels of antigen in 
vivo is one possible way to avoid such interference. The 
ability of hemagglutinin/ nucleoprotein (HA/NP) vaccine 
in a recombinant vector has been shown to overcome 
maternal antibody to SIV. The objectives of this study 
were to determine if 1) virus-like replicon particle (RP) 
vaccine expressing the HA gene induced an active 
immune response in pigs lacking maternal antibodies and 
2) RP vaccine expressing HA  could overcome maternal 
antibodies to SIV. The objectives were determined  via a 
vaccination-challenge study.  
 
Materials and Methods 
 Pigs came from two sources and their incorporation 
in the study is shown in Table 1.  One source was SIV 
antibody negative and did not use SIV vaccine; the other 
source routinely used SIV vaccine in gilts and sows. 
Neither source had experienced recent clinical outbreaks 
of swine influenza.  Piglets for the vaccination-challenge 
study that are naïve or had maternal antibody came from 
pregnant swine that received either a sham or a 
commercially available inactivated SIV H3N2 vaccine.  
Piglets were weaned at 2 ½ weeks, transported to the ISU 
livestock infectious disease isolation facility and divided 
into 6 groups of 10 pigs each. At 3 and 5 weeks of age 
(Day 0 and 14) pigs either received the RP vaccine or a 
placebo intramuscularly (IM). All pigs were challenged 
intratracheally (IT) with 10 ml of 1x107 TCID50 (50% 
tissue culture infectious dose) of virulent cluster 4 H3N2 
SIV (homologous to HA used in RP vaccine) at Day 53. 
Pigs were monitored for increased temperature and 
euthanized 4 days post-inoculation (PI, Day 57).  Tissues 
were collected for quantitative gross lung lesion scoring, 
homologous hemagglutination inhibition (HI) assay, and 
virus titration. 
 To construct the RP vaccine, replicon plasmids 
containing the HA gene and helper plasmids containing 
Venezuelan Equine Encephalitis Virus (VEEV) capsid or 
glycoprotein genes were prepared.  To prepare a replicon 
with the homologous HA gene, the gene was PCR 
amplified using specific primers.  The PCR products 
encoded for unique EcoRV and AscI restriction sites at 
the 5’ and 3’ ends, respectively.  The PCR products were 
then cloned into a transfer vector, pCRII-Blunt 
(Invitrogen) and sequenced to ensure no errors were 
introduced into the gene during PCR amplification. Each 
gene was then cloned into a replicon vector using the 
unique EcoRV and AscI restriction sites. RNA transcripts 
were produced in vitro (RiboMAX T7 Express, Promega) 
from the replicon and helper plasmids and purified, 
followed by agarose gel analysis to assess integrity, and 
quantification by ultraviolet (UV) absorbance. The 
replicon and helper RNAs were mixed with Vero cells in 
electroporation chambers and pulsed. Replicon 
electroporated cells were incubated at 37°C for 18 hours. 
Cell lysates were prepared from electroporated cells for 
Western blot analysis. RP was harvested from culture 
fluids and the infectious titer of the RP preparation was 
measured by antigen-specific IFA. RP were tested in a 
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cytopathic effect (CPE) assay to assure the absence of 
detectable replication-competent virus.  
 The HI assay was performed on sera stored at -20C.  
Geometric means at 5 time points (Day 0, 14, 28, 53 and 
57) were determined for each group.  
 Nasal swabs and lung lavage fluid were collected and 
viral amount determined by qPCR performed.  Bronchial 
alveolar lavage (BAL) fluid was collected by pipetting 50 
ml of sterile DMEM with antibiotics into the lungs and 
collected into sterile 15 ml tubes and stored at -80C until 
titration.  
 Analysis of variance (ANOVA) was used to analyze 
results from gross lung lesion scoring, log 2 transformed 
serum HI titers, and log 10 transformed virus titers from 
nasal swabs and BAL fluid. Rectal temperature data was 
also analyzed via ANOVA. 
 
Results and Discussion 
 Rectal temperatures in all sham treated groups (1 and 
3) and group 4 increased day 1 PI when compared to day 
0 PI (Figure 1). This demonstrates the ability of SIV 
challenge to cause a febrile response that persisted for a 
day.  The group with no maternal antibody given HA RP 
vaccine (group 2) did not have a significant temperature 
increase at day 1 PI when compared to day 0 PI (Figure 
1). This demonstrates the ability of the RP vaccine to 
significantly reduce the febrile affect of SIV challenge.   
 The HA RP vaccine induced a strong antibody 
response when given to piglets with no maternal antibody 
(Group 2).  The geometric mean HI 14 days after the last 
vaccine was administered (day 28) and day 0 PI was 368 
and 92 respectively.  The sham group (group 1) was 
negative on the HI test at these time points.  This 
demonstrates that the source is serologically naïve and 
sham vaccinated pigs remained so during the study.  The 
HA RP vaccine induced a robust immune response that 
was detected by HI. The maternal antibody positive 
groups 3 and 4 had geometric mean titers of 260 and 422 
respectively at day 0.  All pigs in these two groups had 
negative titers (<40) at the day of challenge, 
demonstrating that maternal antibody had waned but the 
HA RP vaccine given at day 0 and 14 did not over come 
maternal interference  
 SIV was not detected via qPCR (<102/ml) in nasal 
swabs day 2 PI in groups 1 and 2 and therefore, the 
amount of virus at this time point in nasal swabs from 
groups 3 and 4 was not determined.  We speculate the 
lack of detectable virus in nasal swabs day 2 PI was 
because high amounts of virus were not being replicated 
and excreted at this time. There was significantly more 
virus detected in nasal swabs and BAL fluid at day 4 PI in 
group 1, 4.1 log 10 and 4.6 log 10/ml respectively, than in 
group 2, 0.5 log 10 and 2.8 log 10/ml respectively .  This 
demonstrated that HA RP vaccine reduced virus amounts 
when pigs were from a serologically naïve source.  The 
amount of virus in lungs 4 days PI in pigs with maternal 
antibody, groups 3 and 4, were the same statistically and 
this shows the HA RP vaccine did not overcome maternal 
antibody.  
 The gross lung lesions were more severe in group 1 
versus group 2, 20.8 percent and 7.4 percent respectively, 
as was neutrophilic exudate evident in histologic 
examination of lungs.  There were no differences in gross 
and microscopic lung lesions in group 3 and 4.  Taken 
together, this demonstrates that lung lesions due to SIV 
are reduced when HA RP vaccine is used in seronegative 
pigs, but not in pigs with maternal antibody.  
 In conclusion, HA RP vaccine reduced the febrile 
response, lung lesions and amount of virus when 
serologically negative pigs are challenged with SIV.  
However, RP vaccine containing HA alone did not 
overcome the inhibitory affects of maternal antibody.   
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Table 1.  Groups for vaccination-challenge pig trial. 
 
Group No.  No. of Pigs Dam Treatment Piglet Treatment Piglet Challenge 
     1       10        Sham          Sham Homologous SIV 
     2       10        Sham         H3 VRP Homologous SIV 
     3       10 Inactivated SIV           Sham Homologous SIV 
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